Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
HubSpot (NYSE: HUBS) is drawing sustained bullish sentiment from Wall Street, with analysts highlighting its deepening penetration into the large enterprise segment as a key growth driver. Recent price target adjustments and partner commentary underscore confidence in the CRM platform's trajectory.
In a significant shift from its long-standing marketing playbook, Pizza Hut will not advertise during NBC's Super Bowl pre-game coverage this year, ending a tradition that spanned over a decade. The move comes as the chain undergoes a strategic review and reallocates its ad budget toward other sports and partnerships.
Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
The Optimism Collective has unveiled OP Enterprise, a comprehensive blockchain infrastructure platform designed to give financial technology firms and institutions direct control over revenue and operations. The launch signals a pivotal shift towards institutional-grade Web3 solutions as regulatory clarity emerges.
Live cattle futures gained ground Friday, supported by steady cash trade, while feeder cattle contracts faced significant pressure. Market attention turns to the upcoming USDA Cattle Inventory report, expected to show a slight decline in total herd numbers.
Cotton futures extended losses on Friday, pressured by a stronger U.S. dollar and a significant year-over-year decline in export commitments. The market's focus remains on demand concerns as key metrics lag behind historical averages.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While the financial sector remains the economy's cornerstone, policy headwinds have capped its recent performance. We analyze one credit rater and a fintech disruptor that show resilience, alongside a legacy asset manager facing challenges.
For long-term investors, volatility presents both opportunity and peril. We examine one stock with explosive potential and two others where caution may be warranted amid shifting market dynamics.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While the small-cap index is a hunting ground for growth, some constituents face significant headwinds. We examine three companies where valuation and market dynamics warrant a cautious approach.
While the small-cap index is famed for its hidden gems, some constituents face headwinds that make them less compelling for growth-focused portfolios. Here's a look at three companies analysts are currently avoiding.
While market attention remains fixated on tech giants, the Russell 2000 index harbors promising, lesser-known companies. We examine three firms with distinct competitive advantages in environmental services, digital health, and private markets.
